AC Immune SA Anno IPO
Cos'è Anno IPO di AC Immune SA?
Anno IPO di AC Immune SA è 2016
Qual è la definizione di Anno IPO?
L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Anno IPO di aziende nel Health Care settore su NASDAQ rispetto a AC Immune SA
Cosa fa AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Aziende con anno ipo simili a AC Immune SA
- The Toronto-Dominion Bank PFD SER 9 3.7% ha Anno IPO di 2015
- Fura Gems ha Anno IPO di 2015
- Hostess Brands ha Anno IPO di 2015
- Nabriva Therapeutics Plc ha Anno IPO di 2015
- REF ha Anno IPO di 2015
- H-Source ha Anno IPO di 2015
- AC Immune SA ha Anno IPO di 2016
- American Pacific Borates ha Anno IPO di 2017
- Razer ha Anno IPO di 2017
- DEAG Deutsche Entertainment Aktiengesellschaft ha Anno IPO di 2017
- Hamilton Beach Brands Co ha Anno IPO di 2017
- Artelo Biosciences ha Anno IPO di 2017
- VARTA AG ha Anno IPO di 2017